1126 The micellar formulation of the TLR7 agonist MBS8(1V270) potentiates the effects of immune checkpoint inhibitors in vivo

1126 The micellar formulation of the TLR7 agonist MBS8(1V270) potentiates the effects of immune checkpoint inhibitors in vivo

Bibliographic Details
Main Authors:	Simon Jensen, Morten Just Petersen, Svetlana Panina
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Enabling In Vivo Optical Imaging of an Osmium Photosensitizer by Micellar Formulation
by: Drashti Shah, et al.
Published: (2022-11-01)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
by: Hong Liang, et al.
Published: (2022-11-01)

607 Regional delivery of a TLR9 agonist to boost checkpoint inhibitor responsiveness in liver metastases
by: Chandra Ghosh, et al.
Published: (2021-11-01)

Withdrawn Paper: Molecules 2005, 10, 1126-1134
by: Derek McPhee
Published: (2007-07-01)

Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo
by: An-cheng Qin, et al.
Published: (2019-04-01)

Effects of formulation conditions on micellar interactions and solution rheology in multi-component micellar systems
by: Nachbar, Leslie Sarah
Published: (2012)

Management by Shoura (MBS) / Norlaila Abdullah
by: Abdullah, Norlaila
Published: (2005)

Resource Allocation for Overlapping MBS Zones
by: Cheng Ray-Guang, et al.
Published: (2011-01-01)

System model reduction for MBS optimization
by: Zavřel J., et al.
Published: (2007-11-01)

Resource Allocation for Overlapping MBS Zones
by: Kuo-Jui Huang, et al.
Published: (2011-01-01)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
by: Caleb Gonzalez, et al.
Published: (2023-01-01)

M.W. Grauwen, Norbertus aartsbisschop van Maagdenburg (1126-1134)
by: W. Simons
Published: (1980-01-01)

M.W. Grauwen, Norbertus aartsbisschop van Maagdenburg (1126-1134)
by: W. Simons
Published: (1980-01-01)

M.W. Grauwen, Norbertus aartsbisschop van Maagdenburg (1126-1134)
by: W. Simons
Published: (1980-01-01)

M.W. Grauwen, Norbertus aartsbisschop van Maagdenburg (1126-1134)
by: W. Simons
Published: (1980-01-01)

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
by: Kerstin Kapp, et al.
Published: (2019-12-01)

MBS : The Rise to Power of Mohammed Bin Salman /
by: Hubbard, Ben, author
Published: (2021)

Sistem sokongan perniagaan mikro (eMBS) /
by: Mohammad Shamil Shaharuddin, 1983-, et al.
Published: (2014)

MAS.622 / 1.126J Pattern Recognition & Analysis, Fall 2000
by: Massachusetts Institute of Technology. Media Laboratory.
Published: (2000)

An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation
by: Nakamura I, et al.
Published: (2017-02-01)

In vitro release and cytotoxicity study of encapsulated sulfasalazine within LTSP micellar/ liposomal and TSP micellar/niosomal nano-formulations
by: Mohammad Javed Ansari, et al.
Published: (2022)

In vitro release and cytotoxicity study of encapsulated sulfasalazine within LTSP micellar/liposomal and TSP micellar/niosomal nano-formulations
by: Mohammad Javed Ansari, et al.
Published: (2022-12-01)

Preparation and Evaluation of Inflammation Targeted Nano-micellar Formulation of Celecoxib
by: Fatemeh BAHADORİ, et al.
Published: (2019-07-01)

A Mixed Micellar Formulation for the Transdermal Delivery of an Indirubin Analog
by: Seol Hwa Seo, et al.
Published: (2020-02-01)

Generalized Radio Resource Management for Overlapping MBS Zones
by: Fang Luo, et al.
Published: (2013-01-01)

液氮冷冻疗法治疗皮肤病1126例疗效观察
by: 田宝通, et al.
Published: (1981-01-01)

A furious prophecy: Cassandra’s rites (Lycophron, Alexandra 1126–73) and Aeschylus’ Eumenides
by: Alexander Sens
Published: (2024-10-01)

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
by: Ti Lu, et al.
Published: (2023-09-01)

Deoxyguanosine is a TLR7 agonist
by: Davenne, T, et al.
Published: (2019)

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
by: Francois Xavier Rwandamuriye, et al.
Published: (2024-12-01)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
by: Jinghua Sun, et al.
Published: (2012-01-01)

TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo.
by: Sergey S Seregin, et al.
Published: (2011-01-01)

Light Guided In-vivo Activation of Innate Immune Cells with Photocaged TLR 2/6 Agonist
by: Keun Ah Ryu, et al.
Published: (2017-08-01)

Real estate securitization in Korea : application of PF ABS and MBS
by: Baek, Jee hee.
Published: (2021)

Sistem sokongan perniagaan mikro (eMBS) [electronic resource] /
by: Mohammad Shamil Shaharuddin, 1983-
Published: (2014)

MBS Vehicle–Crossing Model for Crossing Structural Health Monitoring
by: Xiangming Liu, et al.
Published: (2020-05-01)

Solidification of uranium mill tailings by MBS-MICP and environmental implications
by: Qianjin Niu, et al.
Published: (2022-10-01)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
by: Rui Chang, et al.
Published: (2023-03-01)

Comparison of human B cell activation by TLR7 and TLR9 agonists
by: Neys Lori, et al.
Published: (2008-07-01)

A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection
by: Jodi F. Hedges, et al.
Published: (2023-04-01)